Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04191681 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
A Phase 4 study of Stage D Heart Failure, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04191681 is a Phase 4 study of Stage D Heart Failure that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04191681, a Phase 4 study of Stage D Heart Failure, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous flow left ventricular assist device (CF-LVAD) implantation compared to usual care oral vasodilator therapy.
Conditions Studied
Interventions
- DRUG Sacubitril-Valsartan
- DRUG Usual care (standard-of-care) arm
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2022-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04191681
The ClinicalTrials.gov registry entry for NCT04191681 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage D Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Sacubitril-Valsartan is the first listed.
NCT04191681 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04191681 about?
NCT04191681 is a clinical study titled "Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study". The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous flow left ventricular assist device (CF-LVAD) implantation compared to usual care oral vasodilator therapy.
What is the current status of trial NCT04191681?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2019-11-08. Estimated completion is 2022-12.
What conditions does trial NCT04191681 study?
This clinical trial studies the following conditions: Stage D Heart Failure.
What interventions are being tested in trial NCT04191681?
The interventions under investigation include: Sacubitril-Valsartan (DRUG), Usual care (standard-of-care) arm (DRUG).
Who is sponsoring clinical trial NCT04191681?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04191681 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.